Skip to main content

Table 1 Demographics and clinical characteristics of the subgroup according to early neurological outcomes

From: The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke

Variable

END group (n = 193)

Neither END nor ENI group (n = 469)

ENI group (n = 398)

P

Demographic characteristics

 Age, years

73.2 ± 11.5

69.6 ± 12.0 a

68.1 ± 12.1 b

0.001

 Male, n (%)

121 (62.7)

319 (68.0)

260 (65.3)

0.303

 BMI, kg/m2

24.4 ± 3.6

24.1 ± 3.5

23.9 ± 3.6

0.242

Vascular risk factors, n (%)

 Hypertension

132 (68.4)

315 (67.2)

275 (69.1)

0.816

 Diabetes mellitus

51 (26.4)

116 (24.7)

77 (19.3) b

0.079

 Dyslipidemia

51 (26.4)

120 (25.6)

114 (28.6)

0.592

 Atrial fibrillation

49 (25.4)

96 (20.5)

75 (18.8)

0.180

 Current smoking

59 (30.6)

149 (31.8)

129 (32.4)

0.903

 Current drinking

69 (35.8)

145 (30.9)

129 (32.4)

0.482

 Previous stroke

38 (19.7)

114 (24.3)

80 (20.1)

0.238

 Peripheral artery disease

11 (5.7)

30 (6.4)

30 (7.5)

0.662

 Coronary artery disease

38 (19.7)

83 (17.7)

81 (20.4)

0.603

Medication use history, n (%)

 Previous antiplatelet

21 (10.9)

88 (18.8) a

91 (22.9) b

0.002

 Previous statin

15 (7.8)

49 (10.4)

42 (10.6)

0.521

 Previous anticoagulation

5 (2.6)

11 (2.3)

5 (1.3)

0.391

Clinical assessment

 NIHSS, score

11 (5, 17)

5 (3, 12) a

8 (4, 14) b,c

0.001

 SBP, mmHg

146.9 ± 23.6

151.8 ± 25.7

148.3 ± 22.6

0.171

 DBP, mmHg

87.8 ± 16.2

89.4 ± 14.4

86.8 ± 14.6 c

0.034

 HT, n (%)

32 (16.6)

37 (7.9) a

13 (3.3) b,c

0.001

 OTT, minute

165.00 (120.00, 200.00)

160.00 (115.00, 200.00)

130.00 (90.00, 180.00) b,c

0.001

 PAO, n (%)

77 (39.9)

134 (28.6) a

91 (22.9) b

0.001

 Endovascular treatment, n (%)

43 (22.3)

77 (16.4)

65 (16.3)

0.148

Stroke subtype, n (%)

0.001

 LAA

73 (37.8)

169 (36.0)

147 (36.9)

 

 CE

62 (32.1)

120 (25.6)

132 (33.2)

 

 SAO

27 (14.0)

138 (29.4) a

83 (20.9)

 

 SOE

8 (4.1)

16 (3.4)

8 (2.0)

 

 SUE

23 (12.0)

26 (5.6) a

28 (7.0)

 

Lesion location, n (%)

0.616

 Anterior circulation

149 (77.2)

357 (76.1)

294 (73.9)

 

 Posterior circulation

44 (22.8)

112 (23.9)

104 (26.1)

 

Laboratory data

 TC, mmol/L

4.41 ± 1.11

4.38 ± 1.11

4.32 ± 1.10

0.591

 TG, mmol/L

1.14 (0.82, 1.68)

1.19 (0.86, 1.70)

1.20 (0.85, 1.75)

0.744

 HDL, mmol/L

1.21 ± 0.68

1.14 ± 0.36

1.13 ± 0.49

0.214

 LDL, mmol/L

2.53 (1.95, 3.20)

2.63 (1.98, 3.23)

2.59 (1.96, 3.27)

0.733

 FBG, mmol/L

7.30 ± 2.95

6.28 ± 2.47 a

6.86 ± 3.19 c

0.001

 Hs-CRP, mg/L

7.25 (2.66, 14.55)

4.28 (2.11, 7.55) a

4.85 (2.16, 8.61) b

0.001

 NLR

6.09 (4.43, 8.02)

4.15 (3.14, 5.26) a

3.17 (2.54, 4.22) b,c

0.001

 PLR

179.1 (122.1, 251.1)

126.7 (98.8, 158.0) a

133.1 (102.5, 168.2) b

0.001

 LMR

3.03 (2.50, 4.13)

3.36 (2.48, 4.34)

3.63 (2.61, 4.52) b

0.014

  1. Abbreviations: END early neurological deterioration, ENI, early neurological improvement, BMI body mass index, NIHSS National Institute of Health Stroke Scale, SBP systolic blood pressure, DBP diastolic blood pressure, HT hemorrhagic transformation, OTT onset to treatment time, PAO proximal arterial occlusion, LAA large-artery atherosclerosis, CE cardioembolism, SAO small-artery occlusion, SOE stroke of other determined etiology, SUE stroke of undetermined etiology, TC total cholesterol, TG triglyceride, LDL low-density lipoprotein, HDL high-density lipoprotein, FBG fasting blood glucose, Hs-CRP hyper-sensitive C-reactive protein, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, LMR lymphocyte-monocyte ratio
  2. aThis variable is different significantly between END group and neither END nor ENI group, P < 0.05
  3. bThis variable is different significantly between ENI group and END group, P < 0.05
  4. cThis variable is different significantly between neither END nor ENI group and ENI group, P < 0.05
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094